Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet

Ha-Neul Choi¹, Min-Jung Kang², Soo-Jin Lee³ and Jung-In Kim⁴

¹Department of Smart Foods and Drugs, School of Food and Life Science, Inje University, 197 Inje-ro, Gimhae, Gyungnam 621-749, Korea
²Food & Nutrition Research Team, Hurom Co., Ltd., 79 Seobu-ro, Gimhae, Gyungnam 621-846, Korea

BACKGROUND/OBJECTIVES: Obesity-associated insulin resistance is a strong risk factor for type 2 diabetes mellitus. The aim of this study was to investigate the effect of myricetin on adiposity, insulin resistance, and inflammatory markers in mice with diet-induced insulin resistance.

MATERIALS/METHODS: Five-week-old male C57BL/6J mice were fed a basal diet, a high-fat, high-sucrose (HFHS) diet, or the HFHS diet containing 0.06% myricetin or 0.12% myricetin for 12 weeks after a 1-week adaptation, and body weight and food intake were monitored. After sacrifice, serum lipid profiles, glucose, insulin, adipocyte-derived hormones, and proinflammatory cytokines were measured. The homeostasis model assessment for insulin resistance (HOMA-IR) was determined.

RESULTS: Myricetin given at 0.12% of the total diet significantly reduced body weight, weight gain, and epidydimal white adipose tissue weight, and improved hypertyglycemia and hypercholesterolemia without a significant influence on food intake in mice fed the HFHS diet. Serum glucose and insulin levels, as well as HOMA-IR values, decreased significantly by 0.12% myricetin supplementation in mice fed the HFHS diet. Myricetin given at 0.12% of the total diet significantly reduced serum levels of leptin, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in mice fed the HFHS diet.

CONCLUSIONS: These findings suggest that myricetin may have a protective effect against diet-induced obesity and insulin resistance in mice fed HFHS diet, and that alleviation of insulin resistance could partly occur by improving obesity and reducing serum proinflammatory cytokine levels.

INTRODUCTION

The prevalence of type 2 diabetes mellitus has increased at an epidemic rate, and it has now become a serious global health problem [1]. Obesity-associated insulin resistance is a strong risk factor for type 2 diabetes, the predominant form of diabetes [2]. In addition, insulin resistance is associated with metabolic syndrome, a cluster of metabolic abnormalities, including glucose intolerance, hypertension, hyperlipidemia, and a non-infective inflammatory state [3]. Metabolic syndrome can increase the risk of cardiovascular diseases (CVD) [4]. CVD is a major complication of type 2 diabetes, and a primary cause of immature death in patients with type 2 diabetes [5]. Thus, it is strongly recommended that the treatment strategy for type 2 diabetes focus on improving insulin resistance [6].

Accumulating evidence suggests that adipokines play an important role in regulating insulin sensitivity, which links obesity and insulin resistance [7,8]. Adipocytes increase the secretion of leptin, a hormone involved in energy expenditure [9], and proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) [10] and interleukin-6 (IL-6) [11], but decrease adiponectin secretion in obesity [12]. Adiponectin is an adipocyte-derived hormone involved in glucose metabolism and increases insulin sensitivity [13], whereas TNF-α and IL-6 play a crucial role in the development of insulin resistance [14]. An obese condition elevates TNF-α and IL-6 to stimulate expression of monocyte chemoattractant protein-1 (MCP-1), a proinflammatory chemokine that induces insulin resistance [15,16]. Thus, suppression of obesity-induced inflammation could be useful for improving insulin resistance.

Myricetin is a bioflavonoid abundant in tea, berries, fruits, and vegetables [17]. The estimated daily intake of myricetin from food sources was about 0.98-1.1 mg per day [18]. Myricetin has been reported to have anti-inflammatory activity in vitro [19-21]. Myricetin reduces secretion of TNF-α and IL-1β in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells [19]. Myricetin inhibits LPS-induced production of IL-12 by downregulating transcription factor nuclear factor kappa-B (NF-κB) binding activity in RAW 264.7 cells [20]. In addition, myricetin decreases IL-1β-induced production of IL-6 in synovial cells [21]. Therefore,

Keywords: Myricetin, obesity, glucose, insulin, inflammation

This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP) (No. 2012015763).

Corresponding Author: Jung-In Kim, Tel. 82-55-320-3236, Fax. 82-55-321-0691, Email. fdsnkiji@inje.ac.kr

Received: February 4, 2014, Revised: May 29, 2014, Accepted: June 13, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
myricetin could have the potential to alleviate obesity-induced insulin resistance through its anti-inflammatory activity.

Myricetin could be a promising therapeutic agent for treatment of type 2 diabetes. Liu et al. reported that injection of myricetin enhances insulin action in rats receiving fructose-rich chow [22]. Chang et al. found that dietary myricetin decreases body weight and improves the blood lipid profile in rats fed a high-fat diet [23]. However, the effect of myricetin on insulin resistance and inflammation in an animal model of type 2 diabetes is not fully understood. Thus, the purpose of this study was to investigate the effect of myricetin on adiposity, insulin resistance, and inflammatory markers in a diet-induced obese, insulin-resistant animal model. It has been reported that C57BL/6J mice fed a high-fat, high-sucrose (HFHS) diet develop obesity and type 2 diabetes [24-26]. In this study the effect of chronic consumption of myricetin on adiposity, blood lipid profile, glucose, insulin, adipocyte-derived hormones, and proinflammatory cytokines was determined in these animals fed HFHS diet.

MATERIALS AND METHODS

Animals and experimental protocol

Five-week-old male C57BL/6J mice (n = 28) were obtained from Bio Genomics, Inc. (Seoul, Korea). They were housed individually in plastic cages in a room with controlled temperature of 24 ± 5°C and a relative humidity of 55 ± 5% and kept on a regular light cycle (06:00-18:00 light, 18:00-06:00 dark). All study procedures were approved by the Animal Resource Center at Inje University (approval no. 2013-8).

The mice were offered commercial chow for a 1-week adaptation period and were then divided randomly into four groups consisting of 7 mice each. One group was offered a basal diet containing 5% corn oil and 65% cornstarch (Control group), and the other three groups received a HFHS diet containing non, 0.06%, or 0.12% of myricetin (HFHS, 0.06 MTN, and 0.12 MTN groups) ad libitum for 12 weeks, respectively (Table 1). The HFHS diet contained 3% corn oil, 33% lard, 10.1% cornstarch, and 27% sucrose. The compositions of the basal and HFHS diets were determined based on previous studies [24-26]. The fat-calorie percentages of the basal and HFHS diets were 11.5% and 57.7%, respectively. HFHS diet contained the same amounts of minerals and vitamins per kilocalorie as the basal diet did. Myricetin was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Casein, D,L-methionine, a mineral mixture, and a vitamin mixture were obtained from ICN Pharmaceuticals Inc. (Costa Mesa, CA, USA) and tert-butyl hydroquinone was purchased from Fluka Co. (Milwaukee, WI, USA). Cornstarch was obtained from Daesang Co. (Seoul, Korea), lard was from the Lotte Samgang Co. (Seoul, Korea), and the sucrose and corn oil were obtained from Cheiljedang Co. (Seoul, Korea). Body weight was measured weekly, and food intake was measured three times per week.

At the end of the experimental period, the mice were sacrificed by heart puncture following an overnight fast. Blood samples were collected immediately and centrifuged at 1,500 g for 15 min to obtain serum, which was stored at -70°C for further analysis. Epidydimal white adipose tissue (WAT) samples were collected and weighed.

Biochemical analyses

Serum glucose, triglyceride, and cholesterol levels were measured by an enzymatic method using commercial kits (Asan Pharmaceutical Co., Seoul, Korea). Serum leptin and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA) using commercial assay kits (BioVendor Laboratorní Medicina a.s, Modrice, the Czech Republic). Serum levels of TNF-α, IL-6, and MCP-1 were also determined using ELISA kits specific for mice (eBioscience, Vienna, Austria). Serum insulin was measured with a commercial ELISA kit (Shibayagi Co., Ltd. Ishihara Shibukawa, Gunma, Japan). Homeostasis model assessment for insulin resistance (HOMA-IR) values were estimated as follows: HOMA-IR = [fasting insulin (μU/mL) × fasting glucose (mmol/L)]/22.5 [27].

Statistical analysis

All data are expressed as means ± standard errors (SE). Differences among groups were assessed by one-way analysis of variance with a post hoc Tukey’s test (P < 0.05). The statistical analysis was performed using SAS ver. 9.2 (SAS Institute, Cary, NC, USA).

RESULTS

Body weight, epidydimal fat pad weight, and food intake

Body weights, weight gains, weights of epidydimal WAT, and food intake of the animals were listed in Table 2. The final body weight, weight gain, and epidydimal WAT weight were significantly higher in the HFHS group than those in the control group (P < 0.05). However, myricetin given at 0.12% of the total diet significantly reduced these levels by 14.0%, 27.6%, and 18.5%, respectively, compared with those in the HFHS group (P < 0.05). These values in the 0.06 MTN group were not significantly

---

**Table 1. Composition of the experimental diets**

| Ingredient            | Group          | Control | HFHS | 0.06 MTN | 0.12 MTN |
|-----------------------|----------------|---------|------|----------|----------|
|                       |                | (%)     |      |          |          |
| Casein                |                | 20.0    | 20.0 | 20.0     | 20.0     |
| Corn starch           |                | 65.0    | 10.1 | 10.04    | 9.98     |
| Sucrose               |                | -       | 27.0 | 27.0     | 27.0     |
| Alphacel              |                | 5.0     | -    | -        | -        |
| Corn oil              |                | 5.0     | 3.0  | 3.0      | 3.0      |
| Lard                  |                | -       | 33.0 | 33.0     | 33.0     |
| Vitamin mixture       |                | 1.0     | 1.4  | 1.4      | 1.4      |
| Mineral mixture       |                | 3.5     | 5.0  | 5.0      | 5.0      |
| D,L-Methionine        |                | 0.3     | 0.3  | 0.3      | 0.3      |
| Choline bitartrate    |                | 0.2     | 0.2  | 0.2      | 0.2      |
| Tert-butyl hydroquinone |              | 0.001   | 0.007| 0.007    | 0.007    |
| Myricetin             |                | -       | -    | 0.06     | 0.12     |

---

1) Mice fed the high-fat, high-sucrose diet
2) Mice fed the HFHS diet containing 0.06% myricetin
3) Mice fed the HFHS diet containing 0.12% myricetin
4) AIN-76 vitamin mixture
5) AIN-76 mineral mixture
6) Antioxidative agent, 0.01 g/50 g lipids
different from those in the HFHS and 0.12 MTN groups. Food intake was not significantly different among the four groups.

**Serum lipids, glucose, and insulin concentrations**

Serum lipids, glucose, and insulin concentrations of the animals were listed in Table 3. Serum triglyceride and cholesterol levels were significantly higher in the HFHS group than those in the control group ($P < 0.05$). However, consumption of 0.12% myricetin significantly lowered serum triglyceride and cholesterol levels by 15.9% and 16.8%, respectively, compared with those in the HFHS group. Serum triglyceride and cholesterol levels in the 0.12 MTN group were not significantly different from those in the control group. Serum triglyceride and cholesterol levels in the 0.06 MTN group were not significantly different from those in the control, HFHS, or 0.12 MTN groups.

Serum glucose and insulin levels were significantly higher in the HFHS group, compared with those in the control group. The 0.12 MTN group showed a 14.0% reduction in glucose and a 16.4% reduction in insulin levels compared with those in the HFHS group. Serum glucose and insulin levels in the 0.06 MTN group were not significantly different from those in the HFHS and 0.12 MTN groups. HOMA-IR values, an index of insulin resistance, were significantly elevated by the HFHS diet compared with those in the control group. Consumption of 0.12% myricetin, but not 0.06% myricetin, significantly decreased these levels by 28.0% compared with those in the HFHS group.

**Serum concentrations of leptin, adiponectin, and proinflammatory cytokines**

Serum leptin in the HFHS group was significantly higher than that in the control group. The 0.12 MTN group showed reduced leptin compared with that in the HFHS group (Fig. 1). Serum leptin in the 0.06 MTN group was not significantly different from that in the HFHS and 0.12 MTN groups. Serum adiponectin levels among the four groups were not significantly different. Serum levels of TNF-α and IL-6 increased significantly in the HFHS group compared to those in the control group (Fig. 2). However, consumption of 0.12% myricetin significantly decreased these levels compared with those in the HFHS group. Serum levels of TNF-α and IL-6 levels of 0.06 MTN group were not significantly different from those in the HFHS and 0.12 MTN groups. Serum MCP-1 levels in the control and HFHS groups were not significantly different. Consumption of 0.12% myricetin tended to decrease MCP-1 levels compared to those in the HFHS group, but the difference was not statistically significant.

**DISCUSSION**

We investigated the beneficial effect of chronic consumption of myricetin on the development of obesity and insulin resistance as well as the modulation of inflammatory markers in C57BL/6J mice fed an HFHS diet. Chronic consumption of HFHS diet induces obesity, hyperinsulinemia, and hyperglycemia in these animals [24-26,28]. In this study, consuming the HFHS diet for 12 weeks resulted in obese C57BL/6J mice, whereas 0.12% dietary myricetin reduced body weight, weight gain, and epidydimal WAT weights in mice fed the HFHS diet by 15.9% and 16.8%, respectively, compared with those in the HFHS group. Serum triglyceride and cholesterol levels in the 0.12 MTN group were not significantly different from those in the control group. Serum triglyceride and cholesterol levels in the 0.06 MTN group were not significantly different from those in the control, HFHS, or 0.12 MTN groups.

Consuming the HFHS diet elevated serum insulin and glucose levels, as well as HOMA-IR relative to the control group (Table 2). However, 0.06% myricetin did not significantly affect these values. Myricetin (0.12%), but not 0.06% myricetin, also effectively reduced serum triglycerides and cholesterol compared to those in HFHS diet fed mice (Table 2). The average daily intake of myricetin by the 0.12 MTN and 0.06 MTN groups was calculated to be 120 ± 7 and 61 ± 3 mg/kg, respectively, based on food intake and average body weight. Previous studies have reported that dietary myricetin administered at 75 mg/kg decreases body weight and epidydimal fat pad weight without a beneficial effect on the blood lipid profile, whereas 150 mg/kg myricetin is effective at exerting anti-obesity effect and improving atherogenic index in rats fed a high fat diet [23]. In our study, 120 mg/kg myricetin inhibited the development of HFHS diet-related obesity and hyperlipidemia in mice. Myricetin induces the expression of hepatic peroxisome-activated receptor-α (PPARα) protein and reduces sterol regulatory element binding protein (SREBP) expression, resulting in increased fatty oxidation in high-fat diet-fed rats [23]. Modifying the expression of these proteins could contribute to improving obesity and hyperlipidemia in mice fed the HFHS diet. Weight management has been suggested to be the most important method of reducing risk factors for cardiovascular complications such as hyperglycemia, hyperlipidemia, and hypertension in obese patients with type 2 diabetes [29]. Thus, myricetin could be beneficial in the management of type 2 diabetes.

Table 2. Body weight, epidydimal fat pad weight, and food intake in mice fed the experimental diets

| Group | Control | HFHS | 0.06 MTN | 0.12 MTN |
|-------|---------|------|---------|---------|
| Initial body weight (g) | 19.2 ± 0.8 | 19.3 ± 0.8 | 19.3 ± 0.8 | 19.4 ± 0.7 |
| Final body weight (g) | 26.3 ± 0.9 | 39.8 ± 1.4 | 37.8 ± 1.4 | 34.2 ± 1.3 |
| Weight gain (g/week) | 0.55 ± 0.03 | 1.59 ± 0.16 | 1.44 ± 0.06 | 1.15 ± 0.11 |
| Food intake (g/day) | 3.24 ± 0.18 | 3.06 ± 0.24 | 2.91 ± 0.23 | 2.71 ± 0.16 |
| Epidydimal fat pad weight (mg/g body weight) | 17.1 ± 1.3 | 37.3 ± 1.9 | 36.5 ± 1.9 | 30.4 ± 1.9 |

1) Control, mice fed the basal diet; HFHS, mice fed the high-fat, high-sucrose diet; 0.06 MTN, mice fed the HFHS diet containing 0.06% myricetin; 0.12 MTN, mice fed the HFHS diet containing 0.12% myricetin

2) Homeostasis model assessment for insulin resistance (HOMA-IR) = (Insulin (μU/mL) × glucose (mmol/L))/22.5

3) Values are mean ± SE (n = 7). Means in the same row not sharing a common letter are significantly different at $P < 0.05$.

Table 3. Serum lipids, glucose, and insulin concentrations in mice fed the experimental diets

| Group | Control | HFHS | 0.06 MTN | 0.12 MTN |
|-------|---------|------|---------|---------|
| Triglyceride (mg/dL) | 99.4 ± 5.5 | 122.6 ± 6.1 | 117.4 ± 4.1 | 103.1 ± 4.7 |
| Total cholesterol (mg/dL) | 98.3 ± 5.2 | 136.8 ± 7.3 | 120.3 ± 5.8 | 113.8 ± 6.0 |
| HDL-cholesterol (mg/dL) | 49.4 ± 3.7 | 58.6 ± 3.8 | 58.0 ± 3.3 | 63.5 ± 3.9 |
| Glucose (mg/dL) | 127.7 ± 6.1 | 160.7 ± 7.0 | 149.6 ± 6.2 | 138.1 ± 5.5 |
| Insulin (μU/mL) | 18.1 ± 1.2 | 34.4 ± 1.7 | 31.5 ± 1.7 | 28.7 ± 1.5 |
| HOMA-IR | 5.7 ± 0.5 | 13.7 ± 1.1 | 11.6 ± 0.6 | 9.9 ± 0.8 |

1) Control, mice fed the basal diet; HFHS, mice fed the high-fat, high-sucrose diet; 0.06 MTN, mice fed the HFHS diet containing 0.06% myricetin; 0.12 MTN, mice fed the HFHS diet containing 0.12% myricetin

2) Homeostasis model assessment for insulin resistance (HOMA-IR) = (Insulin (μU/mL) × glucose (mmol/L))/22.5

3) Values are mean ± SE (n = 7). Means in the same row not sharing a common letter are significantly different at $P < 0.05$. 
Fig. 1. Serum leptin and adiponectin levels in the mice fed the experimental diets. A, Leptin; B, Adiponectin. Values are presented as mean ± SE (n = 7). Each bar with different letters is significantly different (P < 0.05). Group abbreviation: Control, mice fed the basal diet; HFHS, mice fed the high-fat, high-sucrose diet; 0.06 MTN, mice fed the HFHS diet containing 0.06% myricetin; 0.12 MTN, mice fed the HFHS diet containing 0.12% myricetin.

Fig. 2. Serum levels of proinflammatory cytokines in the mice fed the experimental diets. A, TNF-α; B, IL-6; C, MCP-1. Values are presented as mean ± SE (n = 7). Each bar with different letters is significantly different (P < 0.05). Group abbreviation: Control, mice fed the basal diet; HFHS, mice fed the high-fat, high-sucrose diet; 0.06 MTN, mice fed the HFHS diet containing 0.06% myricetin; 0.12 MTN, mice fed the HFHS diet containing 0.12% myricetin.

3), suggesting that the HFHS diet induced insulin resistance. It was reported that the injection of myricetin (1 mg/kg per injection, thrice daily) improved insulin resistance in rat fed a high-fructose diet [22]. Yang et al. [28] reported that HFHS diet-induced hyperinsulinemia and hyperglycemia are related to the downregulation of genes involved in insulin signaling. In the present study, 0.12% myricetin was effective for decreasing insulin and HOMA-IR in mice fed the HFHS diet and reduced serum glucose levels near to those of the control group, suggesting that myricetin improved insulin resistance and hyperglycemia.

Although consuming the HFHS diet did not significantly influence serum adiponectin, it elevated serum leptin levels, which was consistent with the results of a previous study [30]. Myricetin (0.12%) decreased leptin compared with that in the HFHS group without significantly influencing adiponectin levels (Fig. 1). Leptin, a hormone produced by adipocytes, reduces food intake and body weight [31]. In an obese condition, leptin signaling is attenuated leading to leptin resistance and hyperleptinemia [32]. Leptin resistance in the brain results in excess triglyceride accumulation in adipose tissue, muscle, liver, and the pancreas, leading to insulin resistance [33]. Myricetin could improve HFHS diet-induced hyperleptinemia by attenuating obesity; thus, contributing to improving insulin sensitivity and

hyperglycemia in these animals.

Myricetin (0.12%) effectively suppressed the HFHS diet-induced elevation in serum TNF-α and IL-6, suggesting an alleviation of obesity-induced low-grade inflammation (Fig. 2). Myricetin at this dose tended to reduce MCP-1 levels in mice fed the HFHS diet, although the difference was not significant. TNF-α and IL-6 modulate insulin signaling, leading to impaired insulin action [10,34]. MCP-1 plays an important role in macrophage infiltration into adipose tissue, which then induces inflammation and insulin resistance [16]. Thus, the reduction
of TNF-α and IL-6 levels by myricetin could have contributed to improving insulin sensitivity in mice fed the HFHS diet. In addition, myricetin induces insulin action on insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase (PI 3-kinase) and translocation of glucose transporter subtype 4 (GLUT4) in high fructose-fed rats [22]. Elevated TNF-α and IL-6 levels are associated with reduced production and availability of endothelial nitric oxide synthase resulting in endothelial dysfunction [35]. Since obesity is an independent risk factor for CVD, reduction in these proinflammatory cytokines by supplementation of myricetin could contribute to decreased risk for CVD. Further study of the effect of myricetin on expression of proinflammatory cytokines and proteins involved in the insulin signaling pathway could be necessary to further understand the mechanisms underlying the improvement in insulin resistance by myricetin in these animals.

In conclusion, myricetin may have a protective effect against diet-induced of obesity and insulin resistance in mice fed HFHS diet, and that alleviation of insulin resistance could partly occur by improving obesity and reducing serum proinflammatory cytokine levels.

REFERENCES

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.

2. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.

3. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109 Suppl 2:S135-48.

4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.

5. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-69.

6. Lebovitz HE. Treating hyperglycemia in type 2 diabetes: new goals and strategies. Cleve Clin J Med 2002;69:809-20.

7. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007;21:1443-55.

8. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-18.

9. Ostlund RE Jr, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 1996;81:3909-13.

10. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.

11. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9.
30. Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K, Itoh M, Suganami T, Ogawa Y. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010;59:2495-504.
31. Pelleymouter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
32. Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 2010;21:643-51.
33. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36.
34. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-6.
35. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959-71.